| Description | The liposome is composed of L-alpha-Phosphatidylcholine, Cholesterol and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (65:30:5). The mean particle size is 100 nm. | Recombinant Ebola Virus-like Particles (EBOV VLPs) are produced in mammalian HEK293 human cells, assembled with Nucleoprotein, Glycoprotein and Matrix protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material Recombinant Ebola Virus-like Particles (EBOV VLPs) are produced in mammalian HEK293 human cells, assembled with Nucleoprotein, Glycoprotein and Matrix protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. EBOV VLPs can be used in the development of EBOV diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More | Creative Biolabs offers a range of recombinant cell lines for Immunotherapy discovery and development. | This product GTTS-WQ7127MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research. | Recombinant O'nyong'nyong Virus-like Particles (ONNV VLPs) are produced in mammalian HEK293 human cells, assembled with E1, E2 and Capsid proteins. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes themRecombinant O'nyong'nyong Virus-like Particles (ONNV VLPs) are produced in mammalian HEK293 human cells, assembled with E1, E2 and Capsid proteins. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. ONNV VLPs can be used in the development of ONNV diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More |